Nifedipine Retard Was as Effective as Angiotensin Converting Enzyme Inhibitors in Preventing Cardiac Events in High-Risk Hypertensive Patients with Diabetes and Coronary Artery Disease: The Japan Multicenter Investigation for Cardiovascular Diseases-B (JMIC-B) Subgroup Analysis
- 1 January 2004
- journal article
- clinical trial
- Published by Japanese Society of Hypertension in Hypertension Research
- Vol. 27 (7) , 449-456
- https://doi.org/10.1291/hypres.27.449
Abstract
We stratified findings from the Japan Multicenter Investigation for Cardiovascular Diseases-B according to whether or not the patients had diabetes and compared the incidence of cardiac events occurring over a 3-year period between treatment with nifedipine retard and angiotensin converting enzyme (ACE) inhibitor. The primary endpoint was the overall incidence of cardiac events (cardiac death or sudden death, myocardial infarction, hospitalization for angina pectoris or heart failure, serious arrhythmia, and coronary interventions), and the secondary endpoints were a composite of other events (cerebrovascular accidents, worsening of renal dysfunction, non-cardiovascular events, and total mortality). The results showed no significant difference in the incidence of the primary endpoint between the nifedipine group (n=199) and the ACE inhibitor group (n=173) in diabetic patients: 15.08% vs. 15.03%, relative risk 1.06, p=0.838. Also in nondiabetic patients, no significant difference was observed between the former (n=629) and the latter (n=649): 13.67% vs. 12.33%, relative risk 1.04, p=0.792. Similar results were obtained for the incidence of the secondary endpoints: in diabetic patients, 5.03% vs. 5.20%, relative risk 0.89, p=0.799; in nondiabetic patients, 2.70% vs. 2.47%, relative risk 1.07, p=0.842. Achieved blood pressure levels were 138/76 and 136/77 mmHg in the nifedipine group and 140/78 and 138/79 mmHg in the ACE inhibitor group in diabetic and nondiabetic patients, respectively. This study showed that nifedipine retard was as effective as ACE inhibitors in reducing the incidence of cardiac events in extremely high-risk hypertensive patients with complications of diabetes and coronary artery disease.Keywords
This publication has 16 references indexed in Scilit:
- Comparison of Nifedipine Retard with Angiotensin Converting Enzyme Inhibitors in Japanese Hypertensive Patients with Coronary Artery Disease: The Japan Multicenter Investigation for Cardiovascular Diseases-B (JMIC-B) Randomized TrialHypertension Research, 2004
- Management of Dyslipidemia in Children and Adolescents With DiabetesDiabetes Care, 2003
- The Evidence Base for Tight Blood Pressure Control in the Management of Type 2 Diabetes MellitusAnnals of Internal Medicine, 2003
- Outcomes With Nifedipine GITS or Co-Amilozide in Hypertensive Diabetics and Nondiabetics in Intervention as a Goal in Hypertension (INSIGHT)Hypertension, 2003
- Major Outcomes in High-Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)JAMA, 2002
- The Prevention or Delay of Type 2 DiabetesDiabetes Care, 2002
- Additional Follow-up from the ABCD Trial in Patients with Type 2 Diabetes and HypertensionNew England Journal of Medicine, 2000
- Effects of Calcium-Channel Blockade in Older Patients with Diabetes and Systolic HypertensionNew England Journal of Medicine, 1999
- Outcome Results of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in Patients With Hypertension and NIDDMDiabetes Care, 1998
- The Effect of Nisoldipine as Compared with Enalapril on Cardiovascular Outcomes in Patients with Non-Insulin-Dependent Diabetes and HypertensionNew England Journal of Medicine, 1998